Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01650805 |
Recruitment Status :
Terminated
(Study terminated based on evaluation of safety data.)
First Posted : July 26, 2012
Results First Posted : October 21, 2014
Last Update Posted : November 17, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Myeloid Leukemia | Drug: ponatinib Drug: imatinib (Gleevec/ Glivec) | Phase 3 |
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
This multicenter, international, phase 3 trial will test the hypothesis that ponatinib is an effective treatment for newly diagnosed CP-CML patients when compared with standard imatinib.
Patients will be randomized in a 1:1 fashion, stratified by Sokal risk score at diagnosis (low, intermediate, high), to receive once daily oral administration of either ponatinib or imatinib. Efficacy measures include molecular, cytogenetic, and hematologic response rates at various timepoints; time to, duration of, and durability of responses; and survival follow-up. Safety measures include clinical laboratory testing, adverse event monitoring, vital signs, physical exams, ECGs, and ECHOs. Other measures include two patient-reported health outcomes questionnaires (FACT-Leu and EQ-5D-5L), determination of mutation status, and, for ponatinib only, measurement of steady-state plasma concentration. Accrual is expected to take approximately 2 years, and patients will be followed for survival for up to 8 years after the last patient's first dose; therefore, patient participation may last up to 10 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 307 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | October 2013 |
Actual Study Completion Date : | October 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: ponatinib |
Drug: ponatinib
45 mg tablet, taken orally once daily |
Active Comparator: imatinib |
Drug: imatinib (Gleevec/ Glivec)
400 mg tablet, taken orally once daily |
- Major Molecular Response (MMR) Rate at 12 Months [ Time Frame: 12 months after first dose ]A ratio of reverse transcribed transcript of BCR-ABL to ABL ≤ 0.1% on the international scale, measured by real-time quantitative polymerase chain reaction.
- MMR Rate [ Time Frame: 5 years after first dose ]To compare the efficacy of ponatinib with imatinib, as measured by MMR rate, at 5 years
- <10% BCR-ABL^IS Rate [ Time Frame: 3 months after first dose ]To compare the proportion of patients achieving a ratio of <10% BCR-ABL to ABL transcript levels at 3 months, as measured by the international scale (<10% BCR-ABL^IS), in patients administered ponatinib versus those administered imatinib
- Complete Cytogenetic Response (CCyR) Rate [ Time Frame: 12 months after first dose ]The percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. Responses are defined as follows: Complete (CCyR): 0% Ph+ metaphases.
- Progression-free Survival [ Time Frame: Up to 8 years after the last patient's first dose ]To compare, according to treatment with ponatinib versus imatinib, progression-free survival
- Overall Survival [ Time Frame: Up to 8 years after the last patient's first dose ]To compare, according to treatment with ponatinib versus imatinib, overall survival

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
CP CML within 6 months of diagnosis
- CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) ≥100 × 10^9/L platelets (≥100,000/mm^3); (v) No evidence of extramedullary disease except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML
-
Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22) Philadelphia chromosome
- (a)Variant translocations are only allowed provided they are assessable for cytogenetic response utilizing conventional cytogenetic techniques; (b) Conventional chromosome banding must be performed; AND (c) A minimum of 20 metaphases must be assessable at entry
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
-
Adequate hepatic function as defined by the following criteria:
(a) Total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome; (b) Alanine aminotransferase (ALT) ≤2.5 × ULN; AND (c) Aspartate aminotransferase (AST) ≤2.5 × ULN
- Adequate renal function as defined as defined by serum creatinine <1.5 x ULN
- Adequate pancreatic function as defined by serum lipase and amylase ≤1.5 × ULN
Exclusion Criteria:
- Received prior imatinib therapy
- Received prior dasatinib therapy
- Received prior nilotinib therapy
- Received, for CML, any other systemic anticancer therapy, experimental therapy, or radiation therapy with the exception of anagrelide or hydroxyurea
- Major surgery within 28 days prior to initiating therapy
- History of bleeding disorder unrelated to CML
- History of acute pancreatitis within 1 year of study or history of chronic pancreatitis
- History of alcohol abuse
- Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)
-
Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- Myocardial infarction, within 6 months prior to randomization
- Unstable angina within 6 months prior to randomization
- Congestive heart failure within 6 months prior to randomization
- History of clinically significant (as determined by the treating physician) atrial arrhythmia or any ventricular arrhythmia
- Any history of ventricular arrhythmia
- Cerebrovascular accident or transient ischemic attack within 6 months prior to randomization
- Any history of peripheral arterial occlusive disease requiring revascularization
- Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
- Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control
- Taking medications that are known to be associated with Torsades de Pointes
- Ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection
- Known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history
- Pregnant or breastfeeding
- Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs
- Diagnosed with or received anticancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)
- Any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the drug

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01650805

Responsible Party: | Ariad Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01650805 |
Other Study ID Numbers: |
AP24534-12-301 |
First Posted: | July 26, 2012 Key Record Dates |
Results First Posted: | October 21, 2014 |
Last Update Posted: | November 17, 2014 |
Last Verified: | October 2014 |
Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases |
Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplasms by Histologic Type Neoplasms Myeloproliferative Disorders Bone Marrow Diseases |
Hematologic Diseases Imatinib Mesylate Ponatinib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |